SCHEMBL4040768

SCHEMBL4040768

O=C(NC1CCCCC1)[C@@H](C1CCOCC1)C1(c2ccc(Cl)cc2)Nc2cc(F)c(F)cc2N1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 7/20 0.43
KCNH2 Q12809 4/20 0.43
CYP3A4 P08684 4/20 0.43
CYP2C9 P11712 3/20 0.43
CYP2D6 P10635 2/20 0.43
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
EPHX1 P07099 3/20 0.38
P2RX7 Q99572 1/20 0.38
ALDH1A1 P00352 2/20 0.37
CYP2C19 P33261 2/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 2/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
KDM1A O60341 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4038576 1.00 NR1H4 (0.43) NR1H4KCNH2CYP3A4CYP2C9CYP2D6
SCHEMBL4037198 0.97 NR1H4 (0.42) NR1H4KCNH2CYP3A4CYP2C9CYP2D6
SCHEMBL4039331 0.95 NR1H4 (0.44) NR1H4KCNH2CYP3A4CYP2C9CYP2D6
SCHEMBL4038118 0.95 NR1H4 (0.44) NR1H4KCNH2CYP3A4CYP2C9CYP2D6
SCHEMBL4035029 0.94 NR1H4 (0.47) NR1H4KCNH2CYP3A4CYP2C9CYP2D6
SCHEMBL4040844 0.94 NR1H4 (0.47) NR1H4KCNH2CYP3A4CYP2C9CYP2D6
SCHEMBL4036457 0.92 NR1H4 (0.43) NR1H4KCNH2CYP3A4CYP2C9CYP2D6
SCHEMBL4035395 0.92 NR1H4 (0.42) NR1H4KCNH2CYP3A4CYP2C9CYP2D6
SCHEMBL4035519 0.92 NR1H4 (0.42) NR1H4KCNH2CYP3A4CYP2C9CYP2D6
SCHEMBL4040912 0.90 NR1H4 (0.49) NR1H4CYP3A4CYP2C9NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3043865-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2016-07-20 EP disclosed
WO-2015036442-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-03-19 WO disclosed
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP disclosed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed